secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2021-10-29T23:59:59+00:00
Accession:  0001104659-21-131410
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iRadimed Q3 revenue up 42% to $10.9M; raises full-year guidance
---------------------------------------------------------------

- Q3 2021 revenue $10.9M (+42% YoY); GAAP diluted EPS $0.20, non-GAAP $0.23.
- Full-year 2021 guidance raised: revenue $41.4-41.6M, GAAP EPS $0.60-0.61, non-GAAP $0.70-0.71.
- Gross profit margin improved to 77.1% from 74.6% in Q3 2020; domestic sales 79.5% of revenue.
- Nine-month operating cash flow $7.9M vs $3.3M; free cash flow $7.5M vs $3.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000110465921131410/0001104659-21-131410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000110465921131410/tm2131304d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-131410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer